PureTech Health (LON:PRTC) Shares Cross Below Fifty Day Moving Average – Time to Sell?

Posted by Brenda Bartman on Jul 21st, 2026

PureTech Health plc (LON:PRTC – Get Free Report) crossed below its 50-day moving average during trading on Monday . The stock has a 50-day moving average of GBX 129.20 and traded as low as GBX 124.53. PureTech Health shares last traded at GBX 125.61, with a volume of 358,950 shares changing hands.

Wall Street Analysts Forecast Growth

Separately, Peel Hunt restated a “buy” rating and issued a GBX 508 target price on shares of PureTech Health in a report on Monday, July 13th. One equities research analyst has rated the stock with a Buy rating, According to MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of GBX 508.

Check Out Our Latest Stock Analysis on PRTC

PureTech Health Stock Performance

The company’s 50-day simple moving average is GBX 129.20 and its 200 day simple moving average is GBX 126.96. The company has a current ratio of 6.59, a quick ratio of 2.51 and a debt-to-equity ratio of 6.33. The stock has a market cap of £305.25 million, a P/E ratio of -2.73 and a beta of 0.79.

Insider Activity at PureTech Health

In related news, insider Sharon Barber-Lui purchased 29,868 shares of the business’s stock in a transaction that occurred on Tuesday, July 7th. The shares were bought at an average cost of GBX 119 per share, with a total value of £35,542.92. Also, insider Michele Holcomb bought 31,481 shares of the company’s stock in a transaction on Wednesday, July 8th. The stock was bought at an average price of GBX 119 per share, for a total transaction of £37,462.39. Insiders purchased a total of 147,849 shares of company stock valued at $17,594,031 over the last quarter. Corporate insiders own 13.35% of the company’s stock.

About PureTech Health

(Get Free Report)

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule. It is also developing technology and products for screening, diagnosis, and treatment of neurological disorders, such as ADHD, autism, and depression through computer software; noninvasive neurostimulation treatment for psychiatric disorders; and combination therapy for schizophrenia.